Status:
RECRUITING
Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborating Sponsors:
ZonMw: The Netherlands Organisation for Health Research and Development
Conditions:
Transfusion
Red Blood Cell
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rationale: In patients supported with extracorporeal membrane oxygenation (ECMO), transfusion of red blood cells (RBC) is very common. This is possibly due to the application of liberal thresholds and...
Detailed Description
Extracorporeal membrane oxygenation (ECMO) is used as a supportive method in case of temporary and potentially reversible cardiac or respiratory failure, refractory to conventional therapies. Over the...
Eligibility Criteria
Inclusion
- Patient is aged 18 years or older;
- Is receiving ECMO;
- (Deferred) informed consent.
Exclusion
- Not expected to survive for 24 hours when assessed;
- Inability to receive blood products;
- (Known) decline to blood transfusions (e.g., Jehovah's Witnesses);
- Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+);
- Received ECMO over 48h before screening for eligibility.
Key Trial Info
Start Date :
November 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
526 Patients enrolled
Trial Details
Trial ID
NCT06560164
Start Date
November 26 2024
End Date
October 1 2029
Last Update
April 8 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Erasme Brussels
Brussels, Brussels Capital, Belgium, 1070
2
KU Leuven, medical IC
Leuven, Flemish Brabant, Belgium, 3000
3
KU Leuven, surgical IC
Leuven, Flemish Brabant, Belgium, 3000
4
CHU Charleroi
Charleroi, Hainaut, Belgium, 6000